NYSE: BHVNBiohaven Ltd Stock
$20.37+1.69 (+9.05%)
Updated Apr 17, 2025
BHVN Price
$20.37
Fair Value Price
N/A
Market Cap
$2.08B
52 Week Low
$15.79
52 Week High
$55.70
P/E
-2.2x
P/B
4.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$846.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.45
Operating Cash Flow
-$582M
Beta
1.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BHVN Overview
Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company targeting neurological diseases, including rare disorders. Its pipeline includes BHV3000-301, BHV3000-302, BHV3000-303, and others. Biohaven Pharmaceutical has a collaboration agreement with Thirty Madison, Inc. d/b/a Cove to facilitate telemedicine evaluations for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BHVN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BHVN
Ranked#413 of 463
Ranked#413 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BHVN news, forecast changes, insider trades & much more!
BHVN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BHVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BHVN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BHVN is poor value based on its book value relative to its share price (4.91x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
BHVN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BHVN due diligence checks available for Premium users.
Valuation
BHVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.2x
Industry
-177.72x
Market
27.98x
BHVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.91x
Industry
4.05x
BHVN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BHVN's financial health
Profit margin
Revenue
$0.0
Net Income
-$186.8M
Profit Margin
0%
BHVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$615.1M
Liabilities
$191.7M
Debt to equity
0.45
BHVN's short-term assets ($538.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BHVN's short-term assets ($538.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BHVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$170.7M
Investing
-$87.7M
Financing
$272.9M
BHVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BHVN vs Biotech Stocks
Biohaven Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.